Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer

Phase 1

• Conditions: Renal Cell Carcinoma; MedDRA version: 21.1Level: LLTClassification code 10038407Term: Renal cell cancerSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2006-006079-19-GB
• Lead Sponsor: niversity College London

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-01-01
• Last Update Posted: 20 July 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 1711

Inclusion Criteria

1.Histologically proven RCC
2.No evidence of residual macroscopic disease on post-operative CT scan after resection of RCC. Patients with clear cell or non-clear cell tumours are eligible
3.Patients with Intermediate or High risk per the Leibovich score 3 to 11
4.Subjects must be >18 years in age without any other medical condition expected to reduce their life expectancy below 10 years from the time of study entry
5.Women of childbearing age must have a negative pregnancy test and must use adequate contraception during the treatment phase of the study and for 9 months afterwards. Women who wish to breast feed are not eligible for the study
6.Adequate bone marrow function (WBC > 3.4x109/l, platelets > 99x109/l), renal function (creatinine < 2.5 x upper limit of normal and hepatic function (LFT < 1.5 x upper limit of normal) within 14 days prior to randomisation
7.Patients should have had surgery at least 4 weeks but no more than 3 months prior to treatment start date
8.Serum Amylase < 1.5 x upper limit of normal
9.Prothrombin (PT) or INR (International Normalized Ratio) and Prothrombin Time (PTT) < 1.5 x upper limit of normal
10.WHO Performance Status 0 or 1 (Appendix 2)
11.Written Informed Consent obtained

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 856
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 855

Exclusion Criteria

1.Prior anti-cancer treatment other than nephrectomy
2.Suspected allergy to sorafenib
3.Cardiac arrhythmias requiring anti-arrhythmics (beta-blockers and digoxin are allowed), symptomatic coronary artery disease or ischaemia, myocardial infarction within the last 6 months, congestive cardiac failure > NYHA Class II
4.Active clinically serious bacterial or fungal infections
5.Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
6.Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Both men and women enrolled in this trial must use adequate birth control
7.Prior malignancy (except for cervical carcinoma in situ or adequately treated basal cell carcinoma)
8.Concomitant medications which have adverse interactions with sorafenib: rifampin, grapefruit juice, ritonavir, ketoconazole, itraconazole and St John's Wort.
9.Patients with uncontrolled hypertension

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified